Dark Report The Dark Report The Dark Report The Dark Report The Dark Report The Dark Report
About The Dark Report
Current Issue Archive Sample Copy Subscribe
shim
Home
shim
The Dark Report
shim
Executive War College
shim
Income Symposium
shim
Audiotapes
shim
Contact Us
The Dark Report
 

       Headlines - May 28, 2013
          Order Article PDF or Hardcopies / Apply for Charter Membersip Today!

R. Lewis Dark: Financial Hurricane Hits Entire Lab Testing Industry

FOR ABOUT 18 MONTHS NOW, THE ENTIRE LABORATORY TESTING INDUSTRY has been hit by an ongoing series of painful cuts to lab test fees and announcements of more restrictive coverage guidelines.

Even today, there is additional news of rock bottom prices to share with you. In this issue, you'll read about Aetna, Inc.'s latest strategy to reduce what it spends on lab testing. Pathologists, for you, the news is a global 88305 fee of just $35.05! Clinical lab managers, your news is an 80053-Comprehensive Metabolic Panel reimbursed by Aetna at $6.54 and an 85027-Complete CBC Automated for which it will pay just $4.00. These prices take effect on July 1, 2013. (See pages 16-18.)

It this a smart move by Aetna? I think not. It is unlikely that routine chemistry panels and CBCs are the primary source of the year-over-year increase in what Aetna and other payers spend on lab testing. Assuming that to be true, could slashing prices for routine assays down to the level of marginal cost prove to be rapidly disruptive to physicians who rely on timely, accurate lab tests to provide patient care that delivers ever-better outcomes? Time will provide that answer.

In the meantime, lab administrators and pathologists must consider the consequences of Aetna's latest price-cutting effort. They cannot view the Aetna pricing in isolation. That is, if labs accept the Aetna pricing, are they foolish enough to believe that UnitedHealthcare, WellPoint, CIGNA, Humana, and other payers are not going to come after them for further price concessions? It would certainly be wise for lab industry associations and professional groups to quickly band together and firmly oppose this latest attempt by a major national health insurer to cram money-losing reimbursement rates on the entire lab industry.

I don't think it is an overstatement to say that the laboratory testing industry is currently beset by a major hurricane of lab test price cuts. At every turn, there is at least one major payer doing one of three things: 1) excluding laboratories as providers from its network; 2) issuing coverage guidelines that restrict beneficiaries' access to certain lab tests; and, 3) arbitrarily dropping the price it pays for significant types of lab tests by substantial amounts. It is essential that lab leaders step forward and fight the battle to maintain fair and adequate reimbursement for the laboratory tests that underpin much of the essential healthcare in this nation.



Not getting The Dark Report in your mailbox every 3 weeks?






Much Uncertainty About Pay for Molecular Codes

Medicare contractors posting prices that are 40% to 50% less than what labs received in 2012

CEO SUMMARY: Having gone unpaid since January 1 for the 114 new molecular CPT codes, many clinical labs and pathology groups have stopped running these tests or laid off staff. Some are considering closing their doors. Evidence indicates that certain Medicare contractors are deciding that some molecular tests are not medically necessary. Medicare officials launched the 60- day comment period on May 9, which gives labs until July 8 to submit comments about pricing and coverage decisions.



Health Insurers See Big Increase in Lab Utilization

Spending on clinical lab testing growing at twice the rate of spending on all other care

CEO SUMMARY: In a recent public workshop, managed care executives revealed that the annual cost of outpatient laboratory testing is increasing at twice the rate of all other medical services. One big driver in the increased spending on lab testing is increased utilization of lab tests by physicians-particularly expensive molecular diagnostic assays and genetic tests. This trend is one reason why private health insurers are taking steps to control the year-over-year increase in the cost of lab testing.



Why One Molecular Diagnostics Company Closed Its Doors

Reimbursement just one of many issues at Pathwork Diagnostics

CEO SUMMARY: When executives closed the doors of Pathwork Diagnostics last month, the simple explanation was that reimbursement for its proprietary molecular diagnostic test was inadequate. Indeed, that was part of the story. But other factors played significant roles in impeding growth at this lab company. Here is an inside look at six factors which contributed to the lab firm's closure.



Managed Care Update: Aetna To Lower Lab Test Prices, New Fees Are Effective on July 1

Move is insurer's latest strategy to reduce what it spends on laboratory testing services



INTELLIGENCE: Late & Latent

Pathologist to Edit Next Cancer Staging Manual

ADD TO: Global Labs






Call us today if you have Charter Membership questions at 800-560-6363 or 512-264-7103
The Dark Report intelligence briefing is delivered to your mailbox every 3 weeks!

See Recent Dark Report Stories and Topics That You May Have Missed!

 

Copyright 2013 © DarkReport.com All rights reserved worldwide •